Table 1.
Baseline clinical characteristics of early IgAN patients
| Variables | Values | |||
|---|---|---|---|---|
| Age (years) |
26 (20–36) |
|||
| Sex (male,%) |
60 (43.8%) |
|||
| Body mass index (kg/m2) |
21.2 (20.0–23.5) |
|||
| Systolic blood pressure (mmHg) |
120 (110–130) |
|||
| Serum creatinine (mg/dL) |
0.90 (0.80–1.09) |
|||
| eGFR (mL/min/1.73 m2) |
85.9 (74.9–100.1) |
|||
| Proteinuria (g/day) |
0.25 (0.11–0.38) |
|||
| Serum cholesterol (mg/dL) |
159 (144–185) |
|||
| Serum albumin (g/dL) |
4.1 (3.9–4.4) |
|||
| Plasma hemoglobin (g/dL) |
13.2 (12.3–14.4) |
|||
| Serum IgA (mg/dL) |
302 (223–417) |
|||
| Follow up duration (months) |
95 (38–207) |
|||
| RAS blockade (N,%) |
66 (43%) |
|||
| Glomerulus number |
37 (20–58) |
|||
| Global sclerosis (%) |
4.0 (0–11.0) |
|||
| Segmental sclerosis (%) |
0 (0–5.0) |
|||
| Crescent formation (yes,%) |
14 (9.2%) |
|||
| WHO grade |
I |
II |
III |
IV |
| |
19 (12.4%) |
84 (54.9%) |
37 (24.2%) |
10 (6.5%) |
| |
None |
Mild |
Moderate |
Severe |
| Mesangial proliferation (yes,%) |
16 (10.7%) |
114 (74.5%) |
16 (10.7%) |
4 (2.6%) |
| Tubular atrophy (yes,%) |
43 (28.1%) |
85 (55.6%) |
19 (12.4%) |
2 (1.3%) |
| Interstitial fibrosis (yes,%) |
30 (19.6%) |
100 (65.4%) |
17 (11.1%) |
2 (1.3%) |
| Interstitial inflammation (yes,%) | 38 (24.8%) | 110 (71.9%) | 1 (0.7%) | 0 (0.0%) |
Continuous variables are presented by median (interquartile range). Categorical variables are presented by frequency (percentage). eGFR, estimated glomerular filtration rate; RAS, renin–angiotensin system.